Estats Units - anglès - NLM (National Library of Medicine)

cardinal health - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 1.25 mg in 0.5 ml

Estats Units - anglès - NLM (National Library of Medicine)

rebel distributors corp - eszopiclone (unii: uzx80k71oe) (eszopiclone - unii:uzx80k71oe) - eszopiclone 2 mg - lunesta is indicated for the treatment of insomnia. in controlled outpatient and sleep laboratory studies, lunesta administered at bedtime decreased sleep latency and improved sleep maintenance. the clinical trials performed in support of efficacy were up to 6 months in duration. the final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only). none known. lunesta is a schedule iv controlled substance under the controlled substances act. other substances under the same classification are benzodiazepines and the nonbenzodiazepine hypnotics zaleplon and zolpidem. while eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, it shares some of the pharmacologic properties of the benzodiazepines. abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for

Estats Units - anglès - NLM (National Library of Medicine)

physicians total care, inc. - ciclesonide (unii: s59502j185) (ciclesonide - unii:s59502j185) - ciclesonide 50 ug - omnaris nasal spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. omnaris nasal spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older. omnaris nasal spray is contraindicated in patients with a hypersensitivity to any of its ingredients.

Canadà - anglès - Health Canada

apotex inc - ciclesonide - spray, metered dose - 50mcg - ciclesonide 50mcg - corticosteroids

Estats Units - anglès - NLM (National Library of Medicine)

rebel distributors corp - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol hydrochloride 1.25 mg in 3 ml - xopenex (levalbuterol hcl) inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. xopenex (levalbuterol hcl) inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol hcl or racemic albuterol.

Estats Units - anglès - NLM (National Library of Medicine)

physicians total care, inc. - ciclesonide (unii: s59502j185) (ciclesonide - unii:s59502j185) - ciclesonide 80 ug - alvesco is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. alvesco is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. alvesco is contraindicated in patients with known hypersensitivity to ciclesonide or any of the ingredients of alvesco. rare cases of hypersensitivity reactions with manifestations such as angioedema, with swelling of the lips, tongue and pharynx, have been reported. teratogenic effects : pregnancy category c oral administration of ciclesonide in rats up to 900 mcg/kg/day (approximately 10 times the maximum human daily inhalation dose based on mcg/m2 /day) produced no teratogenicity or other fetal effects. however, subcutaneous administration of ciclesonide in rabbits at 5 mcg/kg/day (less than the maximum human daily inhalation dose based on mcg/m2 /day) or greater produced fetal toxicity. this included fetal loss, reduc

Estats Units - anglès - NLM (National Library of Medicine)

physicians total care, inc. - levalbuterol tartrate (unii: ads4i3e22m) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 45 ug - xopenex hfa (levalbuterol tartrate) inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease. xopenex hfa (levalbuterol tartrate) inhalation aerosol is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any other component of xopenex hfa inhalation aerosol. xopenex hfa ® (levalbuterol tartrate) inhalation aerosol before using your xopenex hfa (levalbuterol tartrate) inhalation aerosol, read the complete instructions carefully. about xopenex hfa inhalation aerosol use only as directed by a doctor. children should use xopenex hfa inhalation aerosol under adult supervision, as instructed by the patient's doctor. xopenex hfa inhalation aerosol is a pressurized metered-dose inhaler that produces an aerosol for oral inhalation. xopenex hfa inhalation aerosol does not contain chlorofluorocarbons (cfcs). the blue actuator (or mouthpiece)